Search Results - "Moore, J O"

Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis by Lanasa, M C, Allgood, S D, Volkheimer, A D, Gockerman, J P, Whitesides, J F, Goodman, B K, Moore, J O, Weinberg, J B, Levesque, M C

“…Monoclonal B-cell lymphocytosis (MBL) is a preclinical hematologic syndrome characterized by small accumulations of CD5 + B lymphocytes. Most MBL share…”
Get full text

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 by Baer, M R, George, S L, Sanford, B L, Mrózek, K, Kolitz, J E, Moore, J O, Stone, R M, Powell, B L, Caligiuri, M A, Bloomfield, C D, Larson, R A

“…Untreated de novo ( n =421) and secondary ( n =189) acute myeloid leukemia (AML) patients ⩾60 years received intensified chemotherapy, including daunorubicin…”
Get full text

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461 by Byrd, J C, Weiss, R B, Arthur, D C, Lawrence, D, Baer, M R, Davey, F, Trikha, E S, Carroll, A J, Tantravahi, R, Qumsiyeh, M, Patil, S R, Moore, J O, Mayer, R J, Schiffer, C A, Bloomfield, C D

“…To examine the prognostic significance of extramedullary leukemia (EML) at presentation in patients with t(8;21)(q22;q22) karyotype. Consecutive patients with…”
Get more information

Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered by BYRD, J. C, DODGE, R. K, SCHIFFER, C. A, BLOOMFIELD, C. D, CARROLL, A, BAER, M. R, EDWARDS, C, STAMBERG, J, QUMSIYEH, M, MOORE, J. O, MAYER, R. J, DAVEY, F

“…To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute…”
Get full text

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia by Weinberg, J B, Volkheimer, A D, Mihovilovic, M, Jiang, N, Chen, Y, Bond, K, Moore, J O, Gockerman, J P, Diehl, L F, de Castro, C M, Rizzieri, D A, Levesque, M C, DeKroon, R, Strittmatter, W J

“…Survival of chronic lymphocytic leukemia (CLL) cells requires sustained activation of the antiapoptotic PI-3-K/Akt pathway, and many therapies for CLL cause…”
Get full text

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells by Mowery, Y M, Weinberg, J B, Kennedy, M N, Bond, K M, Moore, J O, Lanasa, M C, Gockerman, J P, Diehl, L F, Pizzo, S V, Cianciolo, G J, Friedman, D R

“…B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell–cell…”
Get full text

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function by DiLillo, D J, Weinberg, J B, Yoshizaki, A, Horikawa, M, Bryant, J M, Iwata, Y, Matsushita, T, Matta, K M, Chen, Y, Venturi, G M, Russo, G, Gockerman, J P, Moore, J O, Diehl, L F, Volkheimer, A D, Friedman, D R, Lanasa, M C, Hall, R P, Tedder, T F

“…Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that…”
Get full text

A Randomized Placebo-Controlled Trial of Recombinant Human Interleukin-11 in Cancer Patients With Severe Thrombocytopenia Due To Chemotherapy by Tepler, Isidore, Elias, Laurence, Smith, John W., Hussein, Mohamad, Rosen, Gerald, Chang, Alex Y.-C., Moore, Joseph O., Gordon, Michael S., Kuca, Bernice, Beach, Kathleen J., Loewy, John W., Garnick, Marc B., Kaye, James A.

“…Thrombocytopenia is a complication of cancer treatment that can limit dose intensity. Interleukin-11 (IL-11) is a growth factor that increases platelet…”
Get full text

Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23 : A cancer and leukemia group B study by MROZEK, K, HEINONEN, K, SCHIFFER, C. A, BLOOMFIELD, C. D, LAWRENCE, D, CARROLL, A. J, KODURU, P. R. K, RAO, K. W, STROUT, M. P, HUTCHISON, R. E, MOORE, J. O, MAYER, R. J

“…Following reports of childhood acute myeloid leukemia (AML) showing that patients with t(9; 11)(p22; q23) have a better prognosis than those with…”
Get full text

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer by Peters, W P, Shpall, E J, Jones, R B, Olsen, G A, Bast, R C, Gockerman, J P, Moore, J O

“…To evaluate the effect of high-dose chemotherapy in the treatment of metastatic breast cancer, we performed a phase II trial of a single treatment with…”
Get more information

The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy by Robben, N C, Pippas, A W, Moore, J O

“…A case of reversible cardiogenic shock linked to 5-fluorouracil (5-FU) was observed. Recognizing the increasing use of 5-FU, the authors tried to map this…”
Get more information

Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow by Sandler, D P, Shore, D L, Anderson, J R, Davey, F R, Arthur, D, Mayer, R J, Silver, R T, Weiss, R B, Moore, J O, Schiffer, C A

“…Cigarette smoking may be a risk factor for leukemia. No detailed biological mechanism has been proposed, but a causal link is made plausible by evidence of…”
Get more information

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone : Cancer and leukemia group b study 9022 by MOORE, J. O, DODGE, R. K, AMREIN, P. C, KOLITZ, J, LEE, E. J, POWELL, B, GODFREY, S, ROBERT, F, SCHIFFER, C. A

“…This study evaluated the effect of filgrastim (granulocyte colony-stimulating factor [G-CSF]) on the duration of granulocytopenia and thrombocytopenia after…”
Get full text

CD7+, CD4 —, CD8 — Acute Leukemia: A Syndrome of Malignant Pluripotent Lymphohematopoietic Cells by Kurtzberg, Joanne, Waldmann, Thomas A., Davey, Michael P., Bigner, Sandra H., Moore, Joseph O., Hershfield, Michael S., Haynes, Barton F.

“…Following our initial observation of in vivo conversion of CD7+ , CD4-. CD8- acute lymphoblastic leukemia (ALL) cells from lymphoid to myeloid lineages (Proc…”
Get full text

Follicular mucinosis as a presenting sign of acute myeloblastic leukemia by Sumner, William T., Grichnik, James M., Shea, Christopher R., Moore, Joseph O., Miller, W.Stacy, Burton, Claude S.

“…Follicular mucinosis is often associated with mycosis fungoides and has been rarely observed to occur with other neoplastic and inflammatory conditions. We…”
Get full text

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 by Moore, Joseph O., George, Stephen L., Dodge, Richard K., Amrein, Philip C., Powell, Bayard L., Kolitz, Jonathan E., Baer, Maria R., Davey, Frederick R., Bloomfield, Clara D., Larson, Richard A., Schiffer, Charles A.

“…The Cancer and Leukemia Group B (CALGB) study 9222 tested the hypothesis that treatment intensification of acute myeloid leukemia (AML) in first remission with…”
Get full text

Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes by MANN, K. P, DECASTRO, C. M, LIU, J, MOORE, J. O, BIGNER, S. H, TRAWEEK, S. T

“…The CD56 antigen is normally expressed on natural-killer cells but has additionally been shown to be present on a variety of hematologic malignancies,…”
Get full text

Predictors of outcome of tricuspid valve replacement in carcinoid heart disease by Robiolio, Paul A., Rigolin, Vera H., Harrison, J. Kevin, Lowe, James E., Moore, Joseph O., Bashore, Thomas M., Feldman, Jerome M.

“…The cardiac valvular surgical experience of patients in the Duke Carcinoid Database was reviewed to assess operative outcome. Of the 604 patients in the…”
Get full text

Study of magnetic tunnel junction read sensors by Ho, M.K., Tsang, C.H., Fontana, R.E., Parkin, S.S., Carey, K.J., Tao Pan, MacDonald, S., Arnett, P.C., Moore, J.O.

“…Unshielded magnetic tunnel junction (MTJ) sensors stabilized by insulating hard magnetic tails have been fabricated. Testing results showed that the control of…”
Get full text

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine by Stone, Richard M., Berg, Deborah T., George, Stephen L., Dodge, Richard K., Paciucci, Paolo A., Schulman, Philip P., Lee, Edward J., Moore, Joseph O., Powell, Bayard L., Baer, Maria R., Bloomfield, Clara D., Schiffer, Charles A.

“…The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and…”
Get full text